[niurenbang] top 10 Chinese innovative drug R & D leaders: who is your elder brother?

"Scientist" and "entrepreneur" are two labels with different attributes In the traditional thinking, there is a magic spell for a scientist to start a business As for EQ, limited by the environment, there are few successful people But on the other hand, in an era of "mass entrepreneurship, mass innovation", we are also looking forward to the brilliant achievements of scientists + entrepreneurs in the pharmaceutical industry There are a group of people who come back from overseas or come from multinational pharmaceutical companies and are labeled as "scientists" and "entrepreneurs" In the past 10 years, the domestic talent introduction plan for innovation has promoted the return of overseas scientists and driven the intensive and vigorous entrepreneurial momentum of the pharmaceutical industry They are just the important leaders in the research and development of new drugs in China, and the common slogan is "to be an innovative drug in China" Some of them have made achievements in the field of innovative drug research and development, some are still in the process of continuous exploration They know the latest science and technology, have international contacts, and are more likely to be favored by capital when they start businesses and make innovative drugs But they also face challenges New drug research and development is not easy Truly innovative technologies and products need to be spent, not only with sufficient funds and appropriate environment, but also with a "reliable" entrepreneurial team Today, they are still leading China to make breakthroughs in the field of innovative drugs with their own efforts, and they are an integral part of promoting China to become one of the world's new drug creation powers E-medicine managers sort out 10 well-known scientists and entrepreneurs with a high degree of activity in the industry, so what are the experiences and experiences of cattle people with two roles? The following scientists rank in no particular order Wang Xiaodong: Wang Xiaodong, one of the founders of Baiji Shenzhou, is the undisputed "ox man" in the life science circle In 2004, he was elected as an academician of the National Academy of Sciences of the United States with outstanding achievements in the field of cell apoptosis, and became the first one among more than 200000 people studying in the United States in mainland China Since 2004, he has been the director of Beijing Institute of life sciences, and his wish to return home is to be China's own innovative medicine In 2010, Wang Xiaodong and Ou Lei Qiang, the former founder of Baonuo technology company, jointly founded Baiji Shenzhou, an enterprise focusing on the research and development of innovative drugs Wang Xiaodong, who focuses on science, and Ou leiqiang, who is good at operation, have formed the best partner, leading Baiji to go all the way to Shenzhou In just a few years, Baiji Shenzhou has become a research and development benchmark enterprise in the Chinese pharmaceutical industry In 2013, the cooperation between Baiji Shenzhou and Merck, a multinational pharmaceutical company, as well as the high agreement price, proved its scientific research ability and product competitiveness to the industry In February 2016, in the context of the delisting of China capital stocks, Baiji Shenzhou bucked the trend and became one of the few domestic start-up biotechnology companies listed in the United States on NASDAQ This shows that the recognition of its products, team and corporate strategy by the capital market has also shocked the entire Chinese pharmaceutical industry Now, the R & D of several core products led by Wang Xiaodong is progressing smoothly Many anti-tumor products, including small molecule chemical drugs and PD-1 monoclonal antibody of international fever, are in the clinical research stage Lu Xianping: Lu Xianping, President and chief scientific officer of Shenzhen microchip Biotechnology Co., Ltd., is a typical representative of overseas returnees who return to China to start their own businesses and do innovative drug research and development He is one of the main initiators and founders of Shenzhen microchip Biotechnology Co., Ltd CCTV news headline was the first to be launched in China in early 2015, China's famous local innovative drug "sidadamines", which was developed by microchip bio Behind the success will always be full of hardships In 2001, Lu Xianping returned to China to start his own business Although at the beginning of the establishment of micro core biology, it has received 6 million US dollars in venture capital, but for innovative drugs with high development cost, it is still a drop in the bucket Since then, he has been working all the way for financing for quite a long time In the most difficult time, he even faced liquidation and change of business In order to solve the financial crisis, micro core biology authorized the overseas rights and interests of sidabamide to Shanghai Asia of the United States at a price of US $28 million, and established new drug research cooperation with Roche After the completion of the second financing in 2007, the micro core biology was on a gradual and stable path Eight years later, it successfully introduced the first original Chinese new drug "xidaban" for the treatment of lymphoid cancer to the world More than 10 years of research and development of xidabantamine has proved Lu Xianping's passion for entrepreneurship, enduring lonely persistence, and enduring the blow For 15 years, what supported Lu Xianping was his belief in innovation "We have proved that China can innovate as well." Today's enviable achievements, as the media comment: "keep the clouds open see the moon." Wang Yinxiang: Wang Yinxiang, President and chief scientist of Beida pharmaceutical, who has been interested in life science for 10 years, returned to China with his partner Ding liming in 2002 to start his own business Zhejiang Beida Pharmaceutical Co., Ltd was established in this period, and Wang Yinxiang was president and chief scientist of Beida pharmaceutical In 2011, Wang Yinxiang presided over the research and development of "exetane hydrochloride Kemena" for lung cancer treatment, which became the first class 1.1 small molecule targeted anti-cancer drug in China, and won the first prize of national science and technology progress The first targeted anti-tumor drug independently developed by the Chinese was an indelible "myth" for the Chinese pharmaceutical market at that time With the rapid sales of Kemena, Beida pharmaceutical industry has achieved rapid development and become a dazzling star of the domestic pharmaceutical industry In November 2016, Beida pharmaceutical officially landed on GEM and entered a new development stage Kemena is not only the soul of Beida pharmaceutical industry, but also the best representative work of Wang Yinxiang, its R & D leader In addition, in 2015, Wang Yinxiang founded Beijing jiakesi new drug R & D Co., Ltd., which is jointly invested by Beida and several VC companies As the chairman of the board, he is still focusing on the research and development of the original research drugs Yu Dechao: Chairman of Xinda biology is in the field of biopharmaceutical Undoubtedly, Xinda biology, under the leadership of Yu Dechao, is a new force in the field of biopharmaceutical research and development in China He, who is also a returned scientist, has been engaged in the research and development of biopharmaceuticals both in the United States and after returning home The former anti-tumor virus drug "ankeri" and the later monoclonal antibody drug "conbercept" make Yu Dechao become a major IP in the field of biological drug R & D innovation Because of this, unlike many new start-up R & D companies, Cinda biology had capital support at the beginning of its establishment In 2006, Yu Dechao founded Suzhou Xinda biology With strong financial support from the capital circle, it can establish a complete industrial chain and a competitive biopharmaceutical talent team in a short time, which makes most R & D enterprises hard to catch up with In particular, the tumor immunotherapy bispecific antibody drug project has won the favor of Lilly, a global pharmaceutical giant, and is willing to pay a high price for it In 2015, the US $1 billion cooperation with Lilly refreshed the amount of new drug R & D cooperation in China, which also made other enterprises envy Whether it is a case of successful financing or international cooperation, Cinda bio has the meaning of "wind vane", which makes the world see the power of China's biopharmaceutical industry Relying on the power of capital and based on independent innovation, it is the industry's recognition that Xinda biology, led by Yu Dechao, creates a new development model for Chinese Biopharmaceutical Enterprises Wu Jingzi: Wu JINZI, chairman of Geli pharmaceutical, had more than 20 years of work experience in the European and American biomedical industry before returning to establish Geli, and had worked in global pharmaceutical enterprises such as Aventis in France and Novartis in Switzerland In 2011, Wu JINZI resigned from the post of global vice president of GlaxoSmithKline, a multinational pharmaceutical company, and returned to China to start his own business He began to devote himself to the research and development of innovative drugs, hoping to bring the best research and development technology and first-class innovative drugs to Chinese patients Although every start-up company has its own story, the Geli pharmaceutical industry under Wu JINZI seems to be "lucky" compared with other innovative R & D enterprises In 2013, Geli pharmaceutical industry came into the public view In 2015, Geli pharmaceutical obtained US $55 million in financing Only two years later, its first innovative drug, hepatitis C drug asc08, is on the market If asc08 is successfully listed in 2017, it means that Geli will list an original research drug in China in the form of patent license in 5 years Ge Li's unique R & D model has been well known in the industry From the research product lines of multinational pharmaceutical companies or overseas cutting-edge biotechnology companies, select products suitable for the Chinese market and Chinese patients in different clinical trial stages, obtain the rights and interests of the Chinese market or larger market, and then through the clinical research, the team's understanding of the product, and finally complete the listing of the product in China 。
Du Ying: Du Ying, chairman and CEO of zaiding pharmaceutical, founder of zaiding pharmaceutical, is a woman in the field of innovative drug research and development in China Du Ying is also a legend in the field of new drug research and development in China, which is not only because she is a female character, but also because of her past career experience Fifteen years ago, after working for Pfizer in the United States for many years, Du Ying returned home with the goal of changing the development status of China's biomedical industry and wanted to create a pharmaceutical company of her own in China An important opportunity for her to return home was when she was invited by tycoon Li Ka Shing holdings and Hutchison Whampoa Co., Ltd to take the helm of a new medical company and Huang pharma In 2006, he Huang pharmaceutical was successfully listed on the London Stock Exchange Five years later, Du Ying left with Huang pharmaceutical When she left, the new drug company had five drugs under research, and created many first ones in China Later, she chose to join Sequoia Capital to take charge of its medical investment business in China During this period, she led the investment in Beida pharmaceutical, xikangshou biology, Huada gene and angel hospital, reflecting a keen industry sense But Du's desire to set up her own pharmaceutical company remains strong In January 2014, she finally founded zaiding medicine This female entrepreneur has won the respect of almost all peers Zaiding pharmaceutical has become a new star in new drug research and development in China It has a high reputation and influence in the industry, and has obtained some drug authorizations from large pharmaceutical companies such as Sanofi and BMS, which are still in the clinical trial stage The development of indigenous innovative drugs remains Du Ying's long-term goal Yang Dajun: there are many R & D and innovation enterprises in China, but in December 2016, Yasheng pharmaceutical completed a round B financing of 500 million yuan, which brought the company into the public's vision, and the huge amount of financing triggered hot discussions in the industry Yang Dajun, chairman of Yasheng pharmaceutical, returned to China in 2009 and founded Yasheng pharmaceutical He is committed to the research and development and industrialization of small molecule anti-cancer drugs The R & D pipeline mainly focuses on the inhibitors of key proteins of apoptosis pathway, the inhibitors of the second and third generations for the kinase mutants in cancer treatment, and the appearance closely related to tumor treatment Inhibitors of genetic targets, etc This is not his first time to start a business Before that, Yang Dajun and Wang shaomeng, who share the same aspiration, jointly established the Asian biology company in the United States to conduct research and development of new target anticancer drugs